These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 20016890)

  • 1. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats.
    Müllauer J; Karch R; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Mairinger S; Müller M; Löscher W; Langer O; Kuntner C
    Nucl Med Biol; 2013 Aug; 40(6):755-63. PubMed ID: 23774004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
    Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
    J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
    Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
    J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
    Bauer M; Karch R; Zeitlinger M; Stanek J; Philippe C; Wadsak W; Mitterhauser M; Jäger W; Haslacher H; Müller M; Langer O
    J Nucl Med; 2013 Aug; 54(8):1181-7. PubMed ID: 23833270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes Coloaded with Elacridar and Tariquidar To Modulate the P-Glycoprotein at the Blood-Brain Barrier.
    Nieto Montesinos R; Béduneau A; Lamprecht A; Pellequer Y
    Mol Pharm; 2015 Nov; 12(11):3829-38. PubMed ID: 26390138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
    J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
    Wanek T; Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Sauberer M; Mairinger S; Strommer S; Wacheck V; Löscher W; Erker T; Müller M; Langer O
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):149-59. PubMed ID: 21983837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier.
    Bankstahl JP; Bankstahl M; Kuntner C; Stanek J; Wanek T; Meier M; Ding XQ; Müller M; Langer O; Löscher W
    J Neurosci; 2011 Jun; 31(24):8803-11. PubMed ID: 21677164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
    Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.
    Bankstahl JP; Bankstahl M; Römermann K; Wanek T; Stanek J; Windhorst AD; Fedrowitz M; Erker T; Müller M; Löscher W; Langer O; Kuntner C
    Drug Metab Dispos; 2013 Apr; 41(4):754-62. PubMed ID: 23305710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data.
    Bauer M; Zeitlinger M; Karch R; Matzneller P; Stanek J; Jäger W; Böhmdorfer M; Wadsak W; Mitterhauser M; Bankstahl JP; Löscher W; Koepp M; Kuntner C; Müller M; Langer O
    Clin Pharmacol Ther; 2012 Feb; 91(2):227-33. PubMed ID: 22166851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.
    Lentzas A; de Gooijer MC; Zuidema S; Meurs A; Çitirikkaya CH; Venekamp N; Beijnen JH; van Tellingen O
    Fluids Barriers CNS; 2024 Aug; 21(1):62. PubMed ID: 39103921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retina Compatible Interactions and Effective Modulation of Blood Ocular Barrier P-gp Activity by Third-Generation Inhibitors Improve the Ocular Penetration of Loperamide.
    Janga KY; Tatke A; Shukla S; Lamichhane SP; Avula B; Wang X; Jablonski MM; Khan IA; Majumdar S
    J Pharm Sci; 2018 Aug; 107(8):2128-2135. PubMed ID: 29678592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier.
    Bauer M; Karch R; Neumann F; Wagner CC; Kletter K; Müller M; Löscher W; Zeitlinger M; Langer O
    J Cereb Blood Flow Metab; 2010 Mar; 30(3):510-5. PubMed ID: 20010957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.
    Wanek T; Kuntner C; Bankstahl JP; Mairinger S; Bankstahl M; Stanek J; Sauberer M; Filip T; Erker T; Müller M; Löscher W; Langer O
    J Cereb Blood Flow Metab; 2012 Nov; 32(11):2002-11. PubMed ID: 22828996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
    Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB
    J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
    Bauer F; Kuntner C; Bankstahl JP; Wanek T; Bankstahl M; Stanek J; Mairinger S; Dörner B; Löscher W; Müller M; Erker T; Langer O
    Bioorg Med Chem; 2010 Aug; 18(15):5489-97. PubMed ID: 20621487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.